CV Therapeutics

Latest Headlines

Latest Headlines

Astellas drops bid for CV Therapeutics

There won't be any bidding war for CV Therapeutics. Japan's Astellas Pharma says it won't challenge Gilead Sciences' $1.4 billion offer for CV, which at $20 a share came in $4 over Astellas' bid. And

Gilead inks $1.4B buyout deal for CV Therapeutics

Gilead Sciences has struck a deal to buy CV Therapeutics for $1.4 billion, paying out $20 a share. The deal comes just weeks after Japan's Astellas revealed that it was willing to pay $16 a share for

Astellas targets CV board in buyout bid

So CV Therapeutics won't play? We'll see about that: Astellas Pharma has a bully-boy gleam in its eye. You can almost hear it saying, "You'll play, buster. So help me, you'll play." Rejected in its

Astellas goes hostile in CV bid

Unable to win over the board of director at CV Therapeutics, Japan's Astellas is taking its $16 a share bid straight to shareholders. And that could set the stage for a battle to oust CEO Louis

Astellas still eyeing CV; Sun, Taro start talking

Here's your daily deal update: Astellas Pharma says it plans to keep pursuing CV therapeutics despite its rejection of a $1 billion offer. And Sun Pharmaceutical Industries and Taro Pharmaceutical

Astellas still hot to buy CV after rejection

CV Therapeutics has once again spurned a takeover offer from Astellas Pharma--which has done nothing to blunt the Japanese company's interest in a takeover. CV rejected Astellas' $16 per share cash

CV rejects Astellas' $1B offer--again

Saying the offer "significantly undervalues the company," CV Therapeutics has reviewed and rejected Astellas Pharma's $1 billion unsolicited bid for CV. The offer was originally presented in

CV taking a new look at $1B buyout bid

Last November, the board at CV Therapeutics spurned Astellas' billion-dollar offer for the company. But the market has changed a lot in the past two months, and CV now says that they'll give

CV Therapeutics reconsiders $1B Astellas offer

CV Therapeutics said it has decided to reconsider Tokyo drugmaker Astellas Pharma's buyout offer. The original offer of $1 billion was presented back in November. At $16 per share, the proposition is

Astellas bids $1B for CV Therapeutics

Japan's Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday's close. And the pharma company,